Research & publications
Original research is at the heart of what we do. For more than 60 years, our experts have published across a wide range of topics from the fundamentals of health economics itself to the challenges facing health care in the UK and internationally.
The latest research and publications
Unlocking the broader value of biologic therapies through biosimilar-enabled access and repositioning
Biologic medicines account for over 40% of global pharmaceutical spend. When originator patents expire, biosimilar competition should drive prices down, generating cost-savings, broadening access, and improving…
Addressing the systemic challenges of underinvestment in prevention
Prevention of ill-health is an underexploited tool for protecting health systems and societies. It offers the potential to curb increasing demand for healthcare services, increase participation…
The impact of inflation on incremental costs in HTA
Inflation reshapes the economic landscape in which new treatments are evaluated. Yet cost-effectiveness thresholds tend to remain fixed over time. This report examines how inflation in…
The impact of inflation on incremental costs in HTA
Inflation reshapes the economic landscape in which new treatments are evaluated.…
The value of fast diagnostics in time-critical infections
Advancing earlier intervention in time‑critical infections Sepsis continues to…
Evaluating novel antimicrobials within EU joint clinical assessments
Antimicrobial resistance (AMR) is a growing global health and economic threat.…
The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity…
The case for adopting a broader perspective on value in Health Technology Assessment
In this Whitepaper, we describe different perspectives that can be adopted in…
Novel devices: optimising drug delivery in multiple myeloma
Biologics: Driving innovation in the treatment of multiple myeloma Biological…
A global landscape analysis of access to tumour-agnostic therapies
Tumour-agnostic (TA) therapies represent a paradigm shift in oncology by…
Capturing the lived experiences of informal care in acute leukemia
Providing informal care to someone living with acute leukemia imposes a severe…
The commercial case for investing in ALS
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive…
Achieving Accelerated Patient Access to Cancer Care in Europe
OHE developed the Accelerated Patient Access to Cancer Care in Europe (APACE)…